For several years now, Biologique recherche products has enjoyed an increased market share in the biotechnology and pharmaceutical industries. This achievement has been made possible through a series of mergers and acquisitions, co-branding arrangements, joint ventures, joint venture partnerships, joint venture investment, as well as novel product development projects and research. One of the most important milestones for the sector came with the acquisition of GenFinder by Celera Genomics, Inc. (a sequencing program developer), which resulted in the founding of the company Phytome Genetics. This acquisition enabled the company to accelerate its development in the areas of:
GenFinder focuses its business resources on the production of next-generation sequencing technologies and expects to derive approximately twelve.6 million dollars through the first five years of business. The main areas of focus will be on: human genetics, metabolite regulation, neuroscience research, and protein purification/factor production. The company expects to apply its technology to the areas of metabolite regulation, neuroscience research, and DNA engineering. The primary product line that it offers will be focused on transcription factor regulation, however, it will also produce other products that will help to enhance the commercialization of human and animal genetics.
Phytome Genetics is focused on the research of all plants, algae, fungi, and marine and freshwater organisms. Its primary product portfolio will consist of both developed and applied products business lines. The company plans to capitalize on its own technologies and acquire new technologies from outside sources. The company’s pipeline will be primarily focused upon: multi-gene expression systems, novel plant and cell line technologies, and soil and feed development and improvement. Acquiring another company that specializes in these areas will be an excellent step towards expanding the scope of Organic Research products business opportunities. This will ensure consistent revenue for both the company and its downstream partners.
A successful acquisition will result in solidifying the competitive landscape of the field. The acquired company’s research products business opportunities will be able to leverage its exclusive and proprietary technologies and apply them across a broader range of applications to create a more stable, higher gross margin, and a more profitable bottom line. The company’s pipeline will be greatly expanded as it acquires a second company that will allow for significant revenue growth and organic revenue growth.
Syner Bio Products is a biotechnology company focusing on the development of synthetic biology solutions to the world’s most pressing health challenges. The Syner group currently consists of six members, with the company focusing on four core areas of bio-medical science. These core areas of science are Systems Biology, Gene Regulation, and Cell and Gene Expression. Syner expects to further its product portfolio in the near future, by acquiring another company in the above mentioned core area. Syner will also continue to build on its consumer and merchant relationships to further strengthen its position as a market leader. In the mean time, Syner will focus its resources on developing products to address the needs of its customers in the areas of: cardiology, cardio vascular, rheumatology, rheumatic arthritis, musculoskeletal, gastroenterology, and otolaryngology.
We have successfully combined Syner’s technological expertise and extensive customer and investor knowledge with our extensive portfolio of Gene Editing solutions. Our Gene Editing company was founded in 2021 by a team of highly skilled researchers and scientists. Our team has extensive experience in the field of Gene Modification and has developed our own Gene Editing technology that we are proud to introduce to the market. Our primary clients are the biotechnology industry. From the research and development stage, to clinical trials and ongoing products testing, we have seen firsthand that our products have been effective in transforming lives.